Lead sponsor
GemVax & Kael
5 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
5
Trials led
0
Ongoing
440
Total enrollment
41
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
5
Trials by status
Completed
4
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)Alzheimer's diseasePh 2Completed199
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer PatientsAlzheimer's diseasePh 2Completed96
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)Study partner/caregiver requiredPh 2Completed78
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011Age 41-85Ph 2Completed67
GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)Alzheimer's diseasePh 2Withdrawnnot disclosed